josh_neiman_beigene_leadership

Josh Neiman

SVP, Chief Commercial Officer, North America and Europe

Josh Neiman joined BeiGene in July 2018 and currently serves as Chief Commercial Officer, North America and Europe. Mr. Neiman is responsible for building and leading the commercial team and operations that will bring BeiGene’s innovative medicines to patients.
Mr. Neiman has broad U.S. and global oncology experience that spans marketing, sales, market access, lifecycle management, data and analytics. Most recently, Mr. Neiman was Vice President, Marketing at Flatiron Health from 2014 through its acquisition by Roche in 2018. Previously, Mr. Neiman served in a progression of commercial leadership roles at Onyx Pharmaceuticals and Genentech, Inc. where he was responsible for multiple aspects of commercialization for Kyprolis® (carfilzomib), Rituxan® (rituximab), Gazyva® (obinutuzumab), and Herceptin® (trastuzumab). Early in his career, Mr. Neiman worked as a research associate in drug discovery at Tao Biosciences and Plexxikon.

Mr. Neiman received his MBA from the Kellogg School of Management at Northwestern University and his B.A. from the University of California, Berkeley, in Molecular and Cell Biology.

You are now leaving BeiGene Australia


BeiGene provides links to web sites of other organizations in order to provide visitors with certain information. A link does not constitute an endorsement of content, viewpoint, policies, products or services of that web site. Once you link to another web site not maintained byBeiGene Australia, you are subject to the terms and conditions of that web site, including but not limited to its privacy policy.

You will be redirected to

Click the link above to continue or CANCEL